Combining bioinformatics and MS-based proteomics: clinical implications
|Published in||Expert Review of Proteomics. 2014, vol. 11, no. 3, p. 269-84|
|Abstract||Clinical proteomics research aims at i) discovery of protein biomarkers for screening, diagnosis and prognosis of disease, ii) discovery of protein therapeutic targets for improvement of disease prevention, treatment and follow-up, and iii) development of mass spectrometry (MS)-based assays that could be implemented in clinical chemistry, microbiology or hematology laboratories. MS has been increasingly applied in clinical proteomics studies for the identification and quantification of proteins. Bioinformatics plays a key role in the exploitation of MS data in several aspects such as the generation and curation of protein sequence databases, the development of appropriate software for MS data treatment and integration with other omics data and the establishment of adequate standard files for data sharing. In this article, we discuss the main MS approaches and bioinformatics solutions that are currently applied to accomplish the objectives of clinical proteomic research.|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research groups||Chimie et protéomique clinique (270)|
|ACOSTA MARTIN, Adelina Elena, LANE, Lydie. Combining bioinformatics and MS-based proteomics: clinical implications. In: Expert Review of Proteomics, 2014, vol. 11, n° 3, p. 269-84. doi: 10.1586/14789450.2014.900446 https://archive-ouverte.unige.ch/unige:42243|